Causality Assessment

The chronological sequence between drug administration and adverse event onset is the most fundamental criterion. A plausible temporal relationship exists when the event occurs after drug exposure within a biologically coherent timeframe.

• Latency period: Time from first dose to event onset must align with the drug's pharmacokinetic profile
• Onset patterns: Acute reactions (minutes to hours) vs. delayed effects (weeks to months)
• Washout correlation: Event resolution should correspond to the drug's elimination half-life

Example: Anaphylaxis occurring within 30 minutes of an IV infusion demonstrates a strong temporal relationship, whereas a malignancy diagnosed 3 days after a single dose lacks biological plausibility.

Dechallenge refers to the withdrawal of the suspected drug and observation of whether the adverse event abates or resolves. A positive dechallenge strengthens the causal association.

• Complete recovery: Event fully resolves after discontinuation
• Partial recovery: Event improves but does not fully resolve
• Negative dechallenge: Event persists unchanged despite withdrawal
• Irreversible events: Death or congenital anomalies preclude dechallenge assessment

A positive dechallenge is particularly compelling when the resolution timeline matches the drug's known elimination kinetics.

Rechallenge involves re-administering the suspected drug after a dechallenge period to observe whether the adverse event recurs. A positive rechallenge is considered the strongest single piece of evidence for causality.

• Intentional rechallenge: Clinically planned re-exposure for diagnostic confirmation
• Accidental rechallenge: Unintended re-exposure due to patient error or oversight
• Ethical constraints: Rechallenge is contraindicated for serious or life-threatening reactions
• Dose-response: Recurrence severity may correlate with re-administered dose

Due to ethical and safety concerns, rechallenge data is rarely available prospectively, making it a high-value but infrequent finding in Individual Case Safety Reports (ICSRs).

A rigorous causality assessment must systematically exclude confounding factors that could explain the adverse event independently of the suspected drug.

• Underlying disease: Disease progression or complications may mimic drug reactions
• Concomitant medications: Drug-drug interactions or independent reactions to co-administered drugs
• Comorbid conditions: Pre-existing conditions that predispose to the observed event
• Environmental exposures: Toxins, dietary factors, or lifestyle contributors

Confounding by indication is a pervasive challenge where the treated condition itself causes the event. For example, a thromboembolic event in a patient receiving an anticoagulant may reflect the underlying hypercoagulable state rather than a drug failure.

Several validated instruments standardize causality evaluation by scoring multiple domains and producing a categorical likelihood determination.

• Naranjo Algorithm: A 10-question scoring system yielding categories from 'doubtful' to 'definite' based on weighted yes/no/unknown responses
• WHO-UMC System: The World Health Organization-Uppsala Monitoring Centre criteria classifying causality into six categories: certain, probable, possible, unlikely, conditional/unclassified, and unassessable
• French Imputability Method: A dual-scoring system evaluating both intrinsic (chronological) and extrinsic (bibliographic) imputability on separate scales

These scales reduce inter-rater variability and provide a structured framework for ICSR assessment during signal validation.

Causality assessment incorporates pharmacological coherence—whether a mechanistic explanation exists for how the drug could produce the observed adverse event.

• Receptor pharmacology: Known on-target or off-target binding profiles that could mediate the event
• Class effects: Adverse events shared across drugs with similar mechanisms of action
• Preclinical toxicology: Animal studies or in vitro data suggesting the event's biological feasibility
• Metabolic pathways: Genetic polymorphisms affecting drug metabolism that predispose certain patients

Lack of biological plausibility does not rule out causality but reduces confidence. Conversely, a well-characterized mechanism substantially strengthens the case, particularly when combined with positive dechallenge/rechallenge data.

A critical clinical criterion for establishing a causal link. A positive dechallenge occurs when an adverse event abates after the suspected drug is withdrawn. A positive rechallenge occurs when the event recurs upon re-administration.

• Positive Rechallenge: Strongest evidence of causality, but often ethically impossible to perform.
• Negative Dechallenge: Failure to resolve after withdrawal may indicate an alternative etiology.
• Application: This information is a core data element in standardized ICSR forms like the E2B (R3).

A critical bias where the underlying disease being treated, rather than the drug itself, is the true cause of the adverse event. For example, a patient prescribed an anti-psychotic for severe schizophrenia may experience a cardiac event due to the disease's physiological stress, not the medication.

• Mitigation: Requires comparison with background incidence rates in the untreated disease population.
• Impact: This is a primary challenge in Signal Validation using spontaneous reporting databases like FAERS.

The quantitative backbone of statistical signal detection in large databases like VigiBase. It identifies drug-event combinations reported more frequently than expected.

• PRR & ROR: Frequentist measures that calculate simple ratios of observed-to-expected reporting.
• EBGM: A Bayesian Shrinkage method that uses prior probabilities to reduce false-positive signals from low-count combinations.
• Output: These calculations generate a numerical score that triggers a Signal Detection review.

Regulatory pillars that contextualize causality. Seriousness Criteria classify an event based on outcome (death, hospitalization, disability). Expectedness determines if the event is already listed in the product's reference safety information.

• SUSAR: A Suspected Unexpected Serious Adverse Reaction is a serious event whose nature is not consistent with the label, requiring expedited reporting.
• Aggregate Reporting: The interplay of causality, seriousness, and expectedness forms the core analysis in a PBRER.

The foundational criterion in causality assessment. It evaluates whether the timing of drug administration is biologically plausible for the onset of the adverse event.

• Latency: Some events (e.g., anaphylaxis) occur within minutes, while others (e.g., cancers) have latency periods of years.
• Challenge: Establishing temporality from unstructured Adverse Event Mentions in clinical notes requires precise extraction of onset dates and drug start/stop dates using Medical Named Entity Recognition.

The systematic exclusion of other causes for the observed event. A robust causality assessment must rule out the patient's underlying disease, concomitant medications, and environmental factors.

• Differential Diagnosis: The clinical process of distinguishing a drug reaction from a disease symptom.
• Data Sources: Excluding alternative causes often requires linking data from the ICSR narrative, lab results, and patient medical history, a task complicated by Concept Drift in real-world data.